Sign In
Buy MLYS
$25.61
+0.240 (+0.95%)
At Close: Jun 23, 2026
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?
06:43pm, Sunday, 21'st Sep 2025
Investors in the biotechnology space have been treated to a couple of big fireworks displays recently. During the month leading up to Sept.
3 Potential Biotech Acquisition Targets
12:53pm, Friday, 19'th Sep 2025
There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have go
It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps
05:41pm, Tuesday, 16'th Sep 2025
Whether it's withering jobs data, renewed signs of inflation or sluggish consumer spending, there's been no shortage of concerning economic news over the past month. And yet, this gloomy backdrop has
What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now?
01:01pm, Tuesday, 09'th Sep 2025
Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts
08:23am, Sunday, 07'th Sep 2025
Investors in search of stocks that can produce dramatic gains in a short time frame will want to turn their heads toward the healthcare sector. A handful of stocks in the space more than doubled in pr
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~
RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and relat
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
08:17am, Wednesday, 03'rd Sep 2025
U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 150 points on Wednesday.
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
09:33pm, Tuesday, 02'nd Sep 2025
RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and relat
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
04:01pm, Tuesday, 02'nd Sep 2025
RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and relat
Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade
10:56am, Monday, 18'th Aug 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 149.7% in Mineralys Therapeutics, Inc. (MLYS). While the effectiveness of this highly sought-after metric is qu
Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call Transcript
12:16am, Wednesday, 13'th Aug 2025
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adam Scott Levy - CFO & Secretary Eric Warren - Chief Commercial Officer Jo
Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 12'th Aug 2025
– Presented and published the positive results from both the Launch-HTN and Advance-HTN pivotal trials at scientific meetings and in JAMA and NEJM – – Pre-NDA meeting scheduled to take place in
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025
04:05pm, Monday, 04'th Aug 2025
RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and relate
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why
01:00pm, Friday, 25'th Jul 2025
Mineralys Therapeutics, Inc. (MLYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
